SBIR/STTR Research Award

GlyCoSAM: Glycolysis coupled S-adenosyl methionine regeneration for cell-free methylation reactions

Award identifier e145296089ccf5dc0dd458dbca862410aae0d9fff71ed9196a15e60450f78d4aAwarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$243,527

Program and phase

SBIR · Phase I

Award year

2024

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
INVIZYNE TECHNOLOGIES INC
Proposal award date
2024-02-01
Contract end date
2025-01-31
UEI
UCL9ZV4PLW23
Solicitation number
PA22-176
Topic code
300

Research abstract

Project Abstract – Invizyne Technologies, Inc Regio- and stereo-specific methylation of natural products and synthetic pharmaceuticals can dramatically improve their physiochemical, biological, and pharmacological properties. Biocatalytic methylations are currently limited by the availability of efficient, scalable regeneration systems for the cofactor S-adenosyl methionine (SAM). We propose a universal in vitro platform for the regeneration of SAM using only methionine and ribose as inexpensive feedstocks. Efficient, low-cost SAM regeneration bridges the gap between small scale high- throughput screening of methyltransferases for novel methylated products and industrial production of lead compounds, which is hampered by the availability of large amounts of SAM. Invizyne has developed a bench-scale, enzyme-based, proof-of-concept SAM regeneration system called SimpleSAM that is able to efficiently convert luteolin to chrysoreriol. In Phase I of this project we will i) optimize this enzyme cascade for longevity, stability, SAM turnover numbers and product yield, ii) expand the system to include C-, N-, and O-methylated targets of interest and iii) replace the currently inefficient ATP regeneration system with a new cell-free cascade to regenerate ATP from low-cost feedstock. The resulting GlyCoSAM platform will expand the current toolkit for sustainable cell-free biomanufacturing and enable the scalable production of methylated natural products, nutraceuticals, and synthetic pharmaceuticals.

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Awards with the same topic code

Verified by an exact topic code match. This is not a text-similarity match.

Research funding history

8 SBIR/STTR records share this UEI (2019–2025). Reported award amounts total $5,353,285. Reported amounts are not federal obligations.

Phases: Phase II, Phase I

Agencies: Department of Health and Human Services, Department of Energy

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.